Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg

Phase 3

Completed

• Conditions: Prostatic Neoplasms
• Interventions: Drug: LMIS 50 mg

• Registration Number: NCT02712320
• Lead Sponsor: Foresee Pharmaceuticals Co., Ltd.

Brief Summary

This is a safety extension of up to 12 months of additional treatment with LMIS 50 mg after the subject has completed 12 months of treatment under Protocol FP01C-13-001 and remain eligible for continued treatment with androgen deprivation therapy. Subjects participating in Protocol FP01C-13-001-EX will be followed for safety only.

Detailed Description

This is a multi-center, open-label, single-arm safety extension study. After completing 12 months of treatment with LMIS 50 mg under Protocol FP01C-13-001 (with last dose under Protocol FP01C-13-001 approximately 6 months prior to Day 0 or Protocol FP01C-13-001-EX) and providing a written informed consent, subjects will be screened against baseline inclusion/exclusion criteria necessary for study eligibility. Eligible subjects will receive LMIS 50 mg from the prefilled syringes (without dilution or other mixing) in up to two single subcutaneous injections given 6 months apart.

Study Timeline

• Study Start: 2016-02
• Study First Submitted: 2016-02-22
• Study First Submitted QC: 2016-03-14
• Study First Posted: 2016-03-18
• Primary Completion: 2017-05
• Study Completion: 2017-12-19
• Results First Submitted: 2018-08-16
• Results First Submitted QC: 2018-08-16
• Results First Posted: 2018-09-12
• Status Verified: 2019-02
• Last Update Submitted: 2019-03-13
• Last Update Posted: 2019-03-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 30

Inclusion Criteria

1. Complete 12 months of treatment with LMIS 50 mg under Protocol FP01C-13-001. If a subject wishes to enter the Extension study after more than 28 days following his end of study visit for Protocol FP01C-13-001, his serum testosterone level should be repeated at the screening visit to confirm that his castrate-level testosterone has been maintained.

2. Laboratory values

   • Absolute neutrophil count ≥ 1,500 cells/µL
   • Platelets≥100,000 cells/µL
   • Hemoglobin ≥ 10 gm/dL
   • Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
   • Aspartate Transaminase (AST/SGOT) ≤ 2.5 × ULN
   • Alanine Aminotransferase (ALT/SGPT) ≤ 2.5 × ULN
   • Serum creatinine ≤ 1.5 mg/dL
   • Lipid profile within acceptable range according to investigator's opinion
   • Serum glucose within acceptable range according to investigator's opinion
   • HgbA1c within acceptable range according to investigator's opinion
   • Clinical chemistries (K, Na, Mg, Ca and P) within acceptable range according to investigator's judgment
   • Urinalysis within normal range according to the investigator's judgment

3. Agree to use male contraceptive methods during study trial

4. In the Investigator's opinion, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol

5. All aspects of the protocol explained and written informed consent obtained *If the patient completed 12 months of treatment with LMIS 50 mg more than 28 days prior to entering the Extension study, the Eastern Cooperative Oncology Group (ECOG), Physical Examination (PE), ECG, laboratory and Prostate Specific Antigen (PSA) tests should be repeated.

If the patient has completed 12 months of treatment with LMIS 50 mg under Protocol FP01C-13-001 within the last 28 days, they will be allowed to enter the Extension study without repeating the testosterone measurements, ECG, PE, laboratory and the PSA tests

Exclusion Criteria

1. Receipt of chemotherapy, immunotherapy, cryotherapy, radiotherapy, or anti-androgen therapy other than LMIS 50 mg under Protocol FP01C-13-001 for treatment of carcinoma of the prostate during the subject's participation in Protocol FP01C-13-001. Radiation for pain control will be allowed during the study.
2. Receipt of any Luteinizing Hormone-releasing Hormone (LHRH) suppressive therapy within 6 months of Screening Visit other than LMIS 50 mg under Protocol FP01C-13-001
3. Subject has used prohibited treatments as listed in the Section 8.2 during participation in Protocol FP01C-13-001.
4. Any pathological event, clinical adverse event, or any change in the subject's status at the end of FP01C-13-001 giving indication to the investigator that further participation in the study may not be the best interest of the subject
5. Investigator considers that it is no longer feasible for the subject to be included in a study of LMIS 50 mg
6. Subjects with persistent, non-castrate testosterone levels judged by the investigator
7. Uncontrolled intercurrent illness that would jeopardize the subject's safety, interfere with the objectives of the protocol, or limit the subject's compliance with study requirements, as determined by the Investigator in consultation with the Sponsor

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
LMIS 50 mg	LMIS 50 mg	50 mg leuprolide mesylate administered subcutaneously, when given as two separate injections 6 months apart (Month 12 and Month 18 from the initiation of Protocol FP01C-13-001)

Primary Outcome Measures

Name	Time	Method
Laboratory Assessments - Urinalysis	48 weeks	Urinalysis was performed to assess the safety profile of LMIS 50 mg during the study period, including pH, specific gravity, and the presences of leukocytes, erythrocytes, or protein.
Number of Participants With Adverse Events	Up to 48 weeks	Evaluate the incidence of adverse events, drug-related adverse events, and serious adverse events
Evaluate the Effect of LMIS 50 mg on Cardiovascular Function	Up to 48 weeks	Use 12-lead resting electrocardiograms (ECGs) to evaluate the effect of LMIS 50 mg on cardiovascular function, such as heart rate, RR interval, QRS complex, PR interval, and QT interval.
Laboratory Assessments - Hematology	48 weeks	Hematology assessments performed in this study included hemoglobin, hematocrit, Red Blood Cell (RBC), White Blood Cell (WBC), platelets, neutrophil, eosinophil, basophil, lymphocyte, monocyte, and HbA1c.
Laboratory Assessments - Biochemistry	48 weeks	Biochemical assessments performed in this study included Alanine Aminotransferase (ALT), Aspartate Transaminase (AST), Alkaline Phosphatase (ALP), total bilirubin, Blood Urea Nitrogen (BUN), serum Cr, potassium, sodium, magnesium, calcium, phosphorus, blood glucose, Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and triglycerides.

Trial Locations

Locations (7)

Urology Centers of Alabama; 🇺🇸 Homewood, Alabama, United States

Carolina Urologic Research Center; 🇺🇸 Myrtle Beach, South Carolina, United States

Idaho Urologic Institute - Meridian; 🇺🇸 Meridian, Idaho, United States

AdvanceMed Research; 🇺🇸 Lawrenceville, New Jersey, United States

Genesis Research, LLC; 🇺🇸 San Diego, California, United States

Carolina Clinical Trials, LLC; 🇺🇸 Concord, North Carolina, United States

Seattle Urology Research Center; 🇺🇸 Burien, Washington, United States